WebThe CUPISCO trial (NCT03498521) is an ongoing, ... Experience with the CUPISCO study has highlighted challenges with standardised screening and diagnostic processes in an international clinical trial and the difficulties inherent in accurate diagnosis of poor-risk CUP. Confirming a CUP diagnosis for a clinical trial with multiple review ... WebJan 11, 2024 · Abstract. Copper (Cu) is an essential trace element involved in the normal physiological processes of animals. However, excessive exposure to Cu can produce …
SASE Studio Workshop Cisco
WebApr 13, 2024 · A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in … WebNov 27, 2024 · Carcinoma of unknown primary origin (CUP) accounts for 2%–5% of newly diagnosed advanced malignancies, with chemotherapy as the standard of care. CUPISCO (NCT03498521) is an ongoing randomized trial using comprehensive genomic profiling (CGP) to assign patients with CUP to targeted or immunotherapy treatment arms based … graduate diploma in teaching early childhood
A Challenging Task: Identifying Patients with ... - Wiley Online …
WebJun 27, 2024 · The findings of this retrospective analysis of carcinoma of unknown primary origin cases validate the experimental treatment arms being used in the CUPISCO study and suggest that future studies including additional biomarkers and treatment arms, such as programmed death‐ligand 1 positivity and genomic loss of heterozygosity, may identify a … WebCUPISCO-Studie Unter unserer Leitung wird derzeit eine große, internationale Therapiestudie (CUPISCO) durchgeführt, mit der untersucht wird ob molekular … WebMar 25, 2024 · CUPISCO is a phase II, randomized, open‐label, active‐controlled, multicenter trial to assess the efficacy and safety of molecularly‐guided therapy based on comprehensive genomic profiling versus platinum‐based standard chemotherapy in poor‐risk CUP (Fig. 1) [ 5 ]. chimis south tulsa